We expect sales at 16% CAGR in FY19-21E while management guided 30-50% more than the average growth of IPM and EBITDA to be rangebound, alluding to be around 34-37%. With Guwahati plant contribution in operating revenues at 61%, the management guided for more capacity utilisation to manufacture more products from Strides portfolio. This helps for better tax management with guidance of 8-10% in FY20E. Guwahati remains to be tax benefit zone till FY24E. With better traction of new products/brands, incremental Rx and net cash position, we expect stronger cash flows and higher return ratios. With stability of sales from the acquired portfolios and better visibility of earnings, we maintain ‘Accumulate’ and retain TP at Rs459 on PE 16x of FY21Eearnigns. We maintian ‘Accumulate’.